主讲人简介：

戴晗博士现任维亚集团首席商务官和投资负责人，强生公司创新顾问。他曾担任全球制药和生物技术公司的研发，商务拓展和外部创新高管，包括在葛兰素史克（GSK）美国研发总部10余年，担任蛋白降解团队的Scientific Leader & GSK Fellow。他成功领导或共同领导多个治疗领域的新药发现，临床前开发，转化医学和生物标志物研究项目，包括肿瘤，免疫、代谢和神经性疾病。他作为Frank and Sara McKnight Fellow，获得德克萨斯大学西南医学中心的分子生物医学科学博士学位，并作为Helen Hay Whitney Fellow在哈佛医学院与霍华德·休斯医学研究所完成了博士后的训练。在著名期刊和会议上发表了50余篇论文、书籍章节、摘要和专利，并担任化学探针科学顾问委员会成员，Faculty Opinions药物发现与设计部门委员，大费城美中医药协会（SAPA-GP）会长和中国科学院强磁场科学中心的客座教授。

讲座内容简介：

The current predominant therapeutic paradigm is based on maximizing drug-receptor occupancy to achieve clinical benefit. This strategy, however, generally requires excessive drug concentrations to ensure sufficient occupancy and efficacy, often contributing to adverse side effects. The proteolysis targeting chimeras (PROTACs) method uses bi-functional molecules to recruit ubiquitin E3 ligases to a specific protein target of interest, catalytically inducing its ubiquitination and degradation, therefore providing efficacy that is not limited by equilibrium occupancy. In addition, PROTACs also allow targeting non-enzymatic scaffolding function and potentially long-acting effect. As the number of E3 ligases amenable to recruitment continues to grow, PROTAC induced-protein degradation represents a new pharmacological strategy for highly efficient chemical protein knockdown with utility both as a chemical biology tool and also potentially as a clinically-useful therapeutic modality.